Hepatitis B vaccine alone may be enough for preventing hepatitis B virus transmission in neonates of HBsAg (+)/HBeAg (−) mothers. Issue 1 (3rd January 2017)

• Record Type: Journal Article
• Authors: Lu, Ying; Liang, Xiao-Feng; Wang, Fu-Zhen; Yan, Ling; Li, Rong-Cheng; Li, Yan-Ping; Zhu, Feng-Cai; Zhai, Xiang-Jun; Li, Jie; Zhuang, Hui
• Is Part Of: Vaccine. Volume 35:Issue 1(2017)
• Page Start: 40
• Page End: 45
• Publication Date: 2017-01-03
• Subjects: HBV hepatitis B virus -- HBsAg hepatitis B virus surface antigen -- HBeAg hepatitis B virus e antigen -- HepB hepatitis B vaccine -- HBIG hepatitis B immunoglobulin -- MTCT mother-to-child transmission -- anti-HBs antibody to hepatitis B virus surface antigen -- anti-HBc antibody to hepatitis B virus core antigen -- ALT alanine aminotransferase -- ULN upper limit of normal -- GMC geometric mean concentration -- CI confidential interval -- RLU relative light unit -- S/CO sample/cut off -- PCR polymerase chain reaction -- nPCR nested polymerase chain reaction -- WHO World Health Organization -- ACIP Advisory Committee on Immunization Practice; Hepatitis B virus -- Hepatitis B virus surface antigen -- Hepatitis B virus e antigen -- Hepatitis B vaccine -- Hepatitis B immunoglobulin -- Mother-to-child transmission; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2016.11.061
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Background and aim: To prospectively evaluate the efficacy of vaccine alone compared with vaccine plus HBIG for preventing HBV transmission in neonates of HBsAg (+)/HBeAg (−) mothers. Methods: Combined immunization is currently recommended for neonates of HBsAg (+) mothers in China. As a result, a randomized design is infeasible due to ethical reasons. In practice, Guangxi Zhuang Autonomous Region and Jiangsu Province implement vaccine alone and vaccine plus HBIG strategies for neonates born to HBsAg (+)/HBeAg (−) mothers, respectively. We alternatively enrolled neonates of HBsAg (+)/HBeAg (−) mothers from these two regions. Three doses of a recombinant yeast-derived hepatitis B vaccine were given at 0, 1 and 6 months with or without HBIG at birth. Results: At 7 months, sera were collected from 132 neonates in Guangxi Zhuang Autonomous Region and 752 neonates in Jiangsu Province. Baseline characteristics of both mothers and neonates were comparable in the two regions. No differences were revealed regarding the occurrence of perinatal HBV transmission with or without HBIG at birth [0.1% (1/752) vs. 0.0% (0/132), p = 1.000]. The anti-HBs response rates were 97.7% (129/132) and 98.5% (740/751) for the neonates with vaccine alone and with HBIG ( p = 0.758), respectively. Vaccine alone induced a significantly higher anti-HBs GMC as compared to vaccine plus HBIG at 7 months of age (1555.3 mIU/mL vs. 654.9 mIU/mL, p < 0.0001). At 12 months of age, protective levels of anti-HBs remained in 97.4% (596/612) and 98.3% (118/120) of the neonates receiving and not receiving HBIG, respectively ( p = 0.771). The neonates receiving combined prophylaxis had a markedly lower anti-HBs GMC (210.7 mIU/mL vs. 297.0 mIU/mL, p = 0.011). Horizontal HBV transmission occurred in none of the successfully immunized neonates for both compared groups at 12 months of age. Conclusions: Vaccine alone may be enough for preventing HBV transmission in neonates of HBsAg (+)/HBeAg (−) mothers.